Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS®
29 Jul 2022
Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
NEXTSTELLIS® oral contraceptive now available in Australia
26 Jul 2022
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets), a first-of-its kind oral contraceptive with a novel estrogen is now available in Australia.
New Chief Financial Officer appointment
22 Jul 2022
Mayne Pharma Group Limited is pleased to announce that Mr Aaron Gray has been appointed as Chief Financial Officer (CFO), effective 29 August 2022.
Wilsons investor conference presentation
26 May 2022
Mayne Pharma Group Limited presentation at Wilsons Rapid Insights conference on 26 May 2022.
Mayne Pharma recipient of $4.8m Federal Government Grant
9 May 2022
Mayne Pharma Group Limited is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful.
Non Executive Director appointment
22 Mar 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ann Custin has accepted an invitation to join the Board of Mayne Pharma, effective 23 March 2022.
Mayne Pharma 2022 Half Year Results Media Release
25 Feb 2022
Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS.
Mayne Pharma expands US dermatology portfolio
10 Feb 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States.
Non Executive Director appointment and retirement
17 Jan 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Kathryn MacFarlane, PharmD, has accepted an invitation to join the Board of Mayne Pharma, effective 1 February 2022.